Conv. Plasma
Nigella Sativa
Peg.. Lambda
Vitamin A
Vitamin C
Vitamin D

Feedback Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Unresolved symptoms 85% primary Improvement Relative Risk Unresolved symptoms (b) 63% Viral clearance 76% Viral clearance (b) 57% Viral clearance (c) 63% Viral clearance (d) 41% Time to viral- 24% Time to viral- (b) 9% Hospitalization time 1% no CI Hospitalization time (b) -4% no CI Ahmed et al. Ivermectin for COVID-19 RCT EARLY TREATMENT Favors ivermectin Favors control
Ahmed, 72 patient ivermectin early treatment RCT: 85% improved symptoms [p=0.09], 76% improved viral clearance [p=0.03], and 1% lower hospitalization
copied to clipboard
A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Ahmed et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191
2 Dec 2020    Source   PDF   Share   Tweet
Small 72 patient RCT of ivermectin and ivermectin + doxycycline showing faster recovery with ivermectin. The ivermectin + doxycycline group uses only a single dose of ivermectin vs. 5 daily doses for the ivermectin group. PCR testing was only done weekly after day 7, therefore hospitalization time may not match symptomatic recovery.
Ivermectin group: 12mg daily for 5 days
Ivermectin + doxycycline: 12mg ivermectin single dose, 200mg doxycycline + 100mg bid 4 days
risk of unresolved symptoms, 85.0% lower, RR 0.15, p = 0.09, treatment 0 of 17 (0.0%), control 3 of 19 (15.8%), NNT 6.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 7, fever, ivermectin (5 days), primary outcome.
risk of unresolved symptoms, 62.7% lower, RR 0.37, p = 0.35, treatment 1 of 17 (5.9%), control 3 of 19 (15.8%), NNT 10, day 7, fever, ivermectin (1 day) + doxycycline.
risk of no viral clearance, 75.6% lower, HR 0.24, p = 0.03, treatment 11 of 22 (50.0%), control 20 of 23 (87.0%), NNT 2.7, adjusted per study, day 7, ivermectin (5 days).
risk of no viral clearance, 56.5% lower, HR 0.43, p = 0.22, treatment 16 of 23 (69.6%), control 20 of 23 (87.0%), NNT 5.8, adjusted per study, day 7, ivermectin (1 day) + doxycycline.
risk of no viral clearance, 63.0% lower, HR 0.37, p = 0.02, treatment 5 of 22 (22.7%), control 14 of 23 (60.9%), NNT 2.6, adjusted per study, day 14, ivermectin (5 days).
risk of no viral clearance, 41.2% lower, HR 0.59, p = 0.19, treatment 9 of 23 (39.1%), control 14 of 23 (60.9%), NNT 4.6, adjusted per study, day 14, ivermectin (1 day) + doxycycline.
time to viral-, 23.6% lower, relative time 0.76, p = 0.02, treatment 22, control 23, ivermectin (5 days).
time to viral-, 9.4% lower, relative time 0.91, p = 0.27, treatment 23, control 23, ivermectin (1 day) + doxycycline.
hospitalization time, 1.0% lower, relative time 0.99, treatment 22, control 23, ivermectin, PCR testing only done weekly after day 7.
hospitalization time, 4.1% higher, relative time 1.04, treatment 23, control 23, ivermectin + doxycycline, PCR testing only done weekly after day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ahmed et al., 12/2/2020, Double Blind Randomized Controlled Trial, Bangladesh, South Asia, peer-reviewed, mean age 42.0, 15 authors, average treatment delay 3.83 days, dosage 12mg days 1-5, the ivermectin + doxycycline group took only a single dose of ivermectin.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop